The Acute Myeloid Leukemia Channel is supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals.
The Community Focus Channel is supported with funding from Johnson & Johnson (Gold).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EHA 2026 | Updated ELN recommendations for MRD monitoring in AML: key insights and takeaways
Maria Teresa Voso, MD, University Tor Vergata, Rome, Italy, shares insights into the updated measurable residual disease (MRD) recommendations published by the ELN in December 2025 for monitoring acute myeloid leukemia (AML), highlighting the inclusion of molecular markers such as FLT3-ITD. Dr Voso outlines the revised follow-up recommendations for acute promyelocytic leukemia (APL), and notes that NPM1 remains a key MRD marker, while flow cytometry is used for patients without trackable mutations. This interview took place at the 31st Congress of the European Hematology Association (EHA) in Stockholm, Sweden.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
